Clinical trials: Botox
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Acne Vulgaris
Clinical Trial To Evaluate ANT-1207 In Subjects With Acne
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.
- Trial name
- NCT01293552
- Testing
- ANT-1207, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 72 people
- Sponsor
- Anterios Inc.
Glabellar Rhytides
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03a (NCT00752297)
- Testing
- Preservative-free Saline, Mentor Purified Toxin
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Mentor Worldwide, LLC
Chronic Migraine, Headaches
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
- Trial name
- NCT01749410
- Testing
- onabotulinumtoxinA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Allergan
Migraine Disorders
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.
- Trial name
- PREDICT (NCT02502123)
- Testing
- No Intervention
- Where
- 15 sites in Canada
- Volunteers
- 215 people
- Sponsor
- Allergan
Glabellar Frown Lines
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).
- Trial name
- Head2Head (NCT00777803)
- Testing
- NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), OnabotulinumtoxinA (Vistabel®)
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 381 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper Limb Spasticity
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After…
- Trial name
- JUNIPER (NCT03821402)
- Testing
- DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U
- Where
- 26 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revance Therapeutics, Inc.
Trigeminal Neuralgia
Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration…
- Trial name
- NCT06410859
- Testing
- Botulinum Toxin Type A for Injection,also known as "HengLi®"
- Where
- China
- Volunteers
- 240 people
- Sponsor
- LKGS_277
Muscle Spasticity
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
This is a prospective, non-interventional, observational study to collect data on the use of botulinum toxin Type A in a routine setting in patients with upper limb adult spasticity.
- Trial name
- NCT01387074
- Testing
- botulinum toxin Type A
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder With Urinary Incontinence
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
- Trial name
- APOLLO (NCT03320850)
- Testing
- OnabotulinumtoxinA and Hydrogel admixture
- Where
- 63 sites in United States, Canada
- Volunteers
- 383 people
- Sponsor
- Allergan
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
- Trial name
- NCT00884234
- Testing
- Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Stroke, Upper Limb Spasticity
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
The purpose of this study is to investigate if early administration (i.e. within 12 weeks after stroke) of Dysport® 500 U injections may delay the appearance or the progression of upper limb symptomatic spasticity.
- Trial name
- ONTIME Pilot (NCT02321436)
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Malaysia, Philippines and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Facial Corrections, Facial Lines
A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections
Different studies have shown the negative effects of aging around the area of the eyes. Signs of aging may contribute to erroneously projected emotions (e.g., anger, tiredness, or sadness) that do not reflect the individual's…
- Trial name
- NCT05647551
- Testing
- BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine
- Where
- 8 sites in Australia, Belgium
- Volunteers
- 73 people
- Sponsor
- AbbVie
Urinary Bladder, Overactive
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice.
- Trial name
- NCT02557971
- Testing
- onabotulinumtoxinA
- Where
- 7 sites in United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Glabellar Lines
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
- Trial name
- NCT06212960
- Testing
- DWP712, BOTOX®
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.
- Trial name
- NCT05089357
- Testing
- AbobotulinumtoxinA
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Upper Limb Injury
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability…
- Trial name
- CARBUR (NCT06245772)
- Where
- 27 sites in France
- Volunteers
- 113 people
- Sponsor
- Ipsen
Vulvodynia
Dysport in Vulvodynia Phase II Study
This study is designed to define optimal doses of Dysport and evaluate its efficacy and safety compared with placebo for the treatment of vulvodynia.
- Trial name
- DYVINIA (NCT03598777)
- Testing
- Botulinum toxin type A
- Where
- 9 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Ipsen